Phuturdex › Drugs › Avipendekin pegol
Drugs in development · updated 11 November 2026
Avipendekin pegol: clinical trials and development status
Other names and codes: NKTR-255
As of 11 November 2026 Avipendekin pegol is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 5 diseases. The most advanced phase is II.
Authorisation
- EU no (EMA)
- Italy not in the AIFA register
- Germany not available
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A long-acting formulation composed of the human cytokine interleukin-15 (IL-15) that is conjugated by polymers, with potential immunomodulating and anti-tumor activities. Upon administration of avipendekin pegol, the IL-15 moiety targets and binds to the alpha subunit of the IL-15 receptor on natural killer (NK) and T-cells, thereby activating the IL-15-mediated pathway. This leads to the expansion and activation of natural killer (NK) cells and memory CD8+ T-cells, thereby enhancing the anti-tumor activity of NKs and long-term memory T-lymphocyte immune responses. This may increase tumor cell killing and decrease tumor cell proliferation. In addition, NKTR-255 may, when combined with a tumor-directed antibody, enhance the antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. IL-15 is a pro-inflammatory cytokine that plays a key role in the regulation of T- and NK cell activation, proliferation and promotion of their anti-tumor effects.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Bladder neoplasm | II | 1 | NCT05327530 |
| Lung neoplasm | II | 1 | NCT05632809 |
| Transitional cell carcinoma | II | 1 | NCT05327530 |
| Burkitt lymphoma | I | 1 | NCT03233854 |
| Residual neoplasm | I | 1 | NCT03233854 |
Sites in Europe
63 sites of the active trials in 7 European countries, 0 recruiting.
- France15
- Italy14
- Spain10
- Belgium8
- Germany8
- Greece4
- United Kingdom4
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on Avipendekin pegol
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.